OnKure Therapeutics, Inc. - Class A Common Stock (NQ:OKUR)
2.909
+0.159
(+5.76%)
Streaming Delayed Price
Updated: 11:19 AM EST, Nov 25, 2025
Add to My Watchlist
Price and Volume
Detailed Quote| Volume | 20,541 |
| Open | 3.016 |
| Bid (Size) | 2.850 (100) |
| Ask (Size) | 2.940 (500) |
| Prev. Close | 2.750 |
| Today's Range | 2.700 - 3.016 |
| 52wk Range | 1.700 - 16.14 |
| Shares Outstanding | 33,655,123 |
| Dividend Yield | N/A |
Top News
More News
Performance
More News
Read More
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
January 17, 2025
Frequently Asked Questions
Is OnKure Therapeutics, Inc. - Class A Common Stock publicly traded?
Yes, OnKure Therapeutics, Inc. - Class A Common Stock is publicly traded.
What exchange does OnKure Therapeutics, Inc. - Class A Common Stock trade on?
OnKure Therapeutics, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for OnKure Therapeutics, Inc. - Class A Common Stock?
The ticker symbol for OnKure Therapeutics, Inc. - Class A Common Stock is OKUR on the Nasdaq Stock Market
What is the current price of OnKure Therapeutics, Inc. - Class A Common Stock?
The current price of OnKure Therapeutics, Inc. - Class A Common Stock is 2.909
When was OnKure Therapeutics, Inc. - Class A Common Stock last traded?
The last trade of OnKure Therapeutics, Inc. - Class A Common Stock was at 11/25/25 11:19 AM ET
What is the market capitalization of OnKure Therapeutics, Inc. - Class A Common Stock?
The market capitalization of OnKure Therapeutics, Inc. - Class A Common Stock is 97.89M
How many shares of OnKure Therapeutics, Inc. - Class A Common Stock are outstanding?
OnKure Therapeutics, Inc. - Class A Common Stock has 98M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.